

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Neurology</b>				
Neurology	Histone deacetylase (HDAC)	<p><i>In vitro</i> studies suggest that inhibiting class I and II HDACs could help treat neurodegenerative diseases or neurological injury. In mouse postnatal cortical neurons, class I and II HDAC inhibitors prevented p53-mediated and p53-independent apoptosis. Next steps include testing HDAC inhibitors in models of neuronal injury or neurodegeneration. D-Pharm Ltd.'s DP-VPA HDAC inhibitor is in Phase I testing to treat depression and migraine and Phase II testing to treat epilepsy. Repligen Corp.'s 4b HDAC inhibitor is in preclinical testing to treat Huntington's disease (HD). Tikvah Therapeutics Inc.'s TIK-201 is in Phase I testing to treat amyotrophic lateral sclerosis (ALS).</p> <p><b>SciBX 2(9); doi:10.1038/scibx.2009.374</b>  <b>Published online March 5, 2009</b></p>	Findings unpatented; licensing status not applicable	<p>Uo, T. <i>et al. J. Neurosci.</i>; published online March 4, 2009;            doi:10.1523/JNEUROSCI.6186-08.2009  <b>Contact:</b> Richard S. Morrison, University of Washington School of Medicine, Seattle, Wash.            e-mail:  <a href="mailto:yael@u.washington.edu">yael@u.washington.edu</a></p>